Correction: Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Tomoki Ito, Tomohiko Kamimura, Toru Kiguchi, Koji Kato, Risa Takenaka, Mariko Kobayashi, Ayumi Ito, Mizu Sakai, Koji Izutsu
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChronic Lymphocytic Leukemia Research · Lymphoma Diagnosis and Treatment · Advanced Breast Cancer Therapies
**Correction: International Journal of Hematology (2024) 120:613–620 ** 10.1007/s12185-024-03832-x
In this article, the sentence beginning ‘Patients with a genetic or chromosomal abnormality had ORRs…’ in the Efficacy section was incorrectly given as ‘Patients with a genetic or chromosomal abnormality had ORRs of at least 50%, specifically 55.3% in patients with 17p deletion, 57.7% in those with TP53 mutation and 50.0% in those with unmutated IGHV (Supplementary Table S2).’ and should have read ‘Patients with a genetic or chromosomal abnormality had ORRs of at least 50%, specifically 61.5% in patients with 17p deletion, 56.3% in those with TP53 mutation and 50.0% in those with unmutated IGHV (Supplementary Table S2).’.